NovoCure Ltd NVCR
We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio®, Optune Lua®, and Optune Pax®, our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of adult patients with newly diagnosed glioblastoma ("GBM") together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. We also have a CE certificate to market Optune Gio for the treatment of GBM in the European Union ("EU"), as well as approval or local registration in the United Kingdom ("UK"), Japan, Canada and certain other countries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M | $494.4M | $351.3M | $248.1M | $177.0M | $82.9M |
| Cost of revenue | $166.9M | $137.2M | $128.3M | $114.9M | $114.9M | $106.5M | $88.6M | $80.0M | $55.6M | $39.9M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M | $387.9M | $262.7M | $168.0M | $121.4M | $36.6M |
| R&D | $224.5M | $209.6M | $223.1M | $206.1M | $201.3M | $132.0M | $79.0M | $50.6M | $38.1M | $41.5M |
| SG&A | $177.7M | $189.8M | $164.1M | $132.8M | $126.1M | $107.4M | $87.9M | $73.5M | $59.1M | $51.0M |
| Total operating expenses | $642.3M | $638.5M | $613.9M | $512.5M | $464.5M | $357.5M | $263.6M | $201.7M | $160.7M | $151.9M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M | $30.4M | -$914.0K | -$33.7M | -$39.3M | -$115.3M |
| Interest expense | $22.2M | $11.7M | $4.9M | $8.1M | $8.8M | $18.1M | $14.6M | $16.9M | $11.7M | $7.3M |
| Pre-tax income | -$136.2M | -$131.2M | -$191.7M | -$81.8M | -$52.1M | $18.1M | -$8.8M | -$45.9M | -$48.5M | -$121.5M |
| Income tax | $23.0K | $37.5M | $15.3M | $10.7M | $6.3M | $1.7M | $1.6M | $17.6M | $13.2M | $10.4M |
| Net income | -$136.0M | -$169.0M | -$207.0M | -$93.0M | -$58.0M | $19.8M | -$7.2M | -$63.6M | -$61.7M | -$131.8M |
| EPS, basic | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | -0.69 | — | — |
| EPS, diluted | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.18 | -0.07 | -0.69 | -0.70 | -1.54 |
| Shares, diluted (wtd. avg.) | 111.5M | 107.8M | 106.4M | 104.7M | 103.4M | 108.9M | 97.2M | 91.8M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $93.5M | $163.8M | $240.8M | $115.8M | $209.6M | $246.2M | $179.4M | $142.8M | $80.7M | $100.0M |
| Receivables | $89.4M | $74.2M | $61.2M | $86.3M | $93.6M | $96.7M | $58.9M | $36.5M | $29.6M | $6.3M |
| Inventory | $41.1M | $35.1M | $38.2M | $29.4M | $24.4M | $27.4M | $23.7M | $22.6M | $22.0M | $25.5M |
| Total current assets | $646.7M | $1.11B | $1.03B | $1.11B | $1.07B | $999.4M | $439.9M | $321.4M | $245.1M | $261.9M |
| Property, plant and equipment | $77.6M | $77.7M | $51.5M | $32.7M | $22.7M | $11.4M | $9.3M | $8.4M | $9.0M | $9.8M |
| Total assets | $804.3M | $1.24B | $1.15B | $1.19B | $1.14B | $1.05B | $479.4M | $339.8M | $265.3M | $282.1M |
| Total current liabilities | $223.2M | $756.4M | $179.1M | $158.8M | $142.6M | $113.6M | $86.3M | $64.6M | $50.2M | $36.9M |
| Long-term debt | $195.0M | $97.3M | $568.8M | $565.5M | $562.2M | $429.9M | $149.4M | $149.3M | $97.3M | $96.2M |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M | $575.5M | $261.7M | $227.5M | $151.7M | $139.7M |
| Retained earnings | -$1.29B | -$1.15B | -$985.5M | -$778.5M | -$685.9M | -$631.1M | -$650.9M | -$643.7M | -$582.3M | -$519.9M |
| Total equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M | $476.5M | $217.8M | $112.3M | $113.6M | $142.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M | $99.1M | $26.6M | -$1.9M | -$33.1M | -$107.6M |
| Depreciation and amortisation | $9.4M | $6.2M | $3.9M | $3.1M | $2.8M | $2.6M | $2.1M | $2.0M | $2.0M | $1.7M |
| Stock-based compensation | $104.8M | $160.0M | $115.6M | $107.0M | $94.9M | $75.7M | $52.4M | $39.8M | $27.1M | $22.1M |
| Capital expenditure | $26.6M | $42.9M | $27.1M | $21.4M | $24.2M | $15.0M | $10.5M | $6.7M | $7.4M | $5.7M |
| Investing cash flow | $437.3M | -$140.2M | $184.1M | -$140.0M | -$144.8M | -$472.8M | -$51.7M | -$5.5M | $8.6M | $13.0M |
| Financing cash flow | -$451.3M | $90.3M | $15.8M | $15.5M | $25.7M | $440.2M | $61.7M | $69.4M | $5.2M | $75.1M |
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001645113-26-000033.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.9M | $177.0M | $248.1M | $351.3M | $494.4M | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Gross profit | $36.6M | $121.4M | $168.0M | $262.7M | $387.9M | $420.2M | $423.0M | $381.1M | $468.0M | $488.5M |
| Net income | -$131.8M | -$61.7M | -$63.6M | -$7.2M | $19.8M | -$58.0M | -$93.0M | -$207.0M | -$169.0M | -$136.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |